BHC(SH:600721) 2 1 Shi Ji Jing Ji Bao Dao·2026-01-07 00:05Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]